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ABSTRACT 14 
A high-throughput multiplexed assay was developed for the differential laboratory diagnosis of foot-15 
and-mouth disease virus (FMDV) from viruses which cause clinically similar diseases of livestock.  16 
This assay simultaneously screens for five RNA and two DNA viruses using multiplexed reverse 17 
transcription PCR (mRT-PCR) amplification coupled with a microsphere hybridization array and flow-18 
cytometric detection.  Two of the seventeen primer-probe sets included in this multiplex assay were 19 
adopted from previously characterized real-time RT-PCR (rRT-PCR) assays for FMDV.  The diagnostic 20 
accuracy of the mRT-PCR was evaluated using 287 field samples, including 248 (true positive n= 213, 21 
true negative n=34) from suspect cases of foot-and-mouth disease collected from 65 countries between 22 
1965 and 2006 and 39 true negative samples collected from healthy animals.  The mRT-PCR assay 23 
results were compared with two singleplex rRT-PCR assays, using virus isolation with antigen-ELISA 24 
as the reference method.  The diagnostic sensitivity of the mRT-PCR assay for FMDV was 93.9% [95% 25 
C.I. 89.8-96.4%], compared to 98.1% [95% C.I. 95.3-99.3%] for the two singleplex rRT-PCR assays 26 
used in combination.  In addition, the assay could reliably differentiate between FMDV and other 27 
vesicular viruses such as swine vesicular disease virus and vesicular exanthema of swine virus.  28 
Interestingly, the mRT-PCR detected parapoxvirus (n=2) and bovine viral diarrhea virus (n=2) in 29 
clinical samples, demonstrating the screening potential of this mRT-PCR assay to identify viruses in 30 
FMDV-negative material not previously recognized using focused single-target rRT-PCR assays. 31 
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INTRODUCTION 32 
Foot-and-mouth disease (FMD) is a highly infectious and contagious vesicular disease affecting 33 
domestic and wild ruminants and swine caused by a single-stranded positive-sense RNA virus having 34 
seven distinct serotypes (A, Asia 1, C, O, SAT 1, SAT 2 and SAT 3) (17).  FMD is endemic in many 35 
countries throughout the world, with serotype O having the highest prevalence, followed by serotype A 36 
(9). Early detection of the virus is critical to minimizing disease spread and the significant economic 37 
implications (12) resulting from the introduction of FMD into a country previously free of the disease.  38 
Diagnosis of FMD can be confounded by diseases with similar clinical signs (“look-alike” diseases), 39 
and by species where presentation of the disease is mild or indistinct (16).  For the laboratory 40 
identification of FMDV, the Office International des Epizooties (OIE) recommends virus isolation (VI), 41 
antigen-ELISA (Ag-ELISA), and RT-PCR with detection by agarose gel electrophoresis or in real-time 42 
using TaqMan® fluorogenic probes (15).   43 
Real-time PCR is widely used by diagnostic laboratories, to complement or as a replacement for more 44 
traditional detection methods.  Two independent real-time reverse transcription polymerase chain 45 
reaction (rRT-PCR) assays for FMD laboratory diagnosis target the ribosomal entry site of the 46 
5´untranslated region (5´UTR) (30) and the viral RNA polymerase gene (3D) (4) on the highly variable 47 
FMDV genome.  The 5´UTR and 3D rRT-PCR assays were initially compared prior to their 48 
implementation in Australia (3). A subsequent in-depth comparative evaluation (14) was conducted to 49 
further evaluate the effectiveness of these assays; demonstrating a higher diagnostic sensitivity of the 50 
rRT-PCR assays over VI and/or antigen-ELISA (35), particularly when both assays were used in 51 
combination.  Both assays are used routinely in combination at the Food and Agriculture Organization 52 
of the United Nations, World Reference Laboratory (FAO WRL) for FMD.  rRT-PCR assays have also 53 
been reported for the detection of other viruses which cause vesicular disease of livestock including 54 
swine vesicular disease (SVD) (29), vesicular stomatitis (VS) (11, 28) and vesicular exanthema of swine 55 
(VES) (31) or symptomatic look-alike diseases including bluetongue (13, 27, 33), bovine viral diarrhea 56 
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(1, 2, 20, 22, 39), malignant catarrhal fever (37) and parapoxvirus (26).   57 
Fluorescent probes for rRT-PCR detection have broad emission spectra which limit multiplexing 58 
capacity to the four or five discrete optical channels typically present in most commercial real-time PCR 59 
instruments.  Therefore, simultaneous testing for FMDV and look-alike disease viruses by rRT-PCR 60 
would require many assays to be run in parallel, thereby increasing the demand on instrumentation and 61 
reagents which escalates costs.  A single multiplexed screening test that simultaneously detects and 62 
differentiates FMDV from look-alike disease viruses would be desirable.  Such a test could facilitate 63 
rapid and cost-effective screening of suspect FMD field samples for laboratory differential diagnosis, 64 
targeted FMD surveillance, or embedded foreign animal disease surveillance whilst conducting routine 65 
testing for endemic diseases. 66 
Luminex xMAP technology is a multiplexed high-throughput detection system (38) with many 67 
applications for nucleic acid detection (6).  The Luminex array offers up to 100 independent channels 68 
using microspheres (5.6 µm) embedded with varying ratios of two fluorescent dyes.  User-defined 69 
surface modifications can include oligonucleotides, antibodies, peptides or other macromolecules. 70 
Typically, a mixed suspension of functionalized microspheres is mixed with the sample to bind analytes 71 
which are then labeled with a fluorescent reporter and analyzed using a specialized flow-cytometer.  The 72 
assay provides end-point detection with qualitative results by comparing fluorescence responses 73 
(median fluorescence intensity, MFI) of each microsphere class to cut-off values.  Recent nucleic acid 74 
applications of the Luminex array include the detection and differentiation of Classical swine fever virus 75 
from other pestiviruses (5), human respiratory viruses (18, 19, 21, 23), human papillomavirus (10, 32) 76 
and human influenza A virus typing (40). 77 
This report describes a novel multiplexed RT-PCR microsphere array assay for the differential 78 
detection of FMDV from look-alike disease viruses. The development, optimization and analytical 79 
evaluation of this multiplex assay will be reported separately.  The primary purpose of this study was to 80 
evaluate the diagnostic performance of the mRT-PCR assay for the detection of FMDV using a panel of 81 
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suspect field samples.  The diagnostic sensitivities of the 3D and 5´UTR FMDV assays in mRT-PCR 82 
format were compared to rRT-PCR using VI with Ag-ELISA as the reference method.  The detection of 83 
look-alike diseases in suspect FMD field samples is also reported. 84 
 85 
MATERIALS AND METHODS 86 
Samples.  The panel comprised epithelia (true positive n= 213, true negative n=34) from suspect field 87 
cases of FMD submitted from 65 countries to the FAO WRL for FMD between 1965 and 2006 and 88 
included representatives of all seven serotypes of FMDV.  In addition, 39 samples of true negative 89 
tongue epithelial were collected from healthy cattle at a UK abattoir.  All sample testing and reference 90 
measurements were conducted at the FAO WRL for FMD.  Epithelia were ground and suspended to 91 
generate a ~10% w/v suspension in phosphate buffer (0.04M, pH 7.6).  The epithelial suspensions (ES) 92 
were centrifuged, the supernatant collected, then stored at -80ºC.  FMDV serotype was determined by 93 
conducting an antigen-ELISA (8) on the original ES or after viral propagation in cell culture.  Samples 94 
of look-alike viruses from the FAO WRL for FMD collection included SVDV, VESV, San Miguel sea 95 
lion virus (SMSV), caliciviruses isolated from a variety of species (including cetacean, bovine, feline, 96 
reptile, skunk) and vesicular stomatitis virus (VSV). 97 
Nucleic acid extraction.  Total nucleic acid was extracted from each ES by an automated procedure 98 
using a MagNA Pure LC (Roche, UK) as previously described (14, 35). Extracted samples (40 µL) were 99 
aliquoted (3×13 µL), stored at -80ºC and thawed once just before use. 100 
rRT-PCR.  Previously reported protocols for the individual 3D (4) and 5´UTR (34) rRT-PCR assays 101 
were modified for use in this study.  Briefly, 25 µl reaction mixes (SuperScriptTM III Platinum® One-102 
Step qRT-PCR System (Invitrogen)) containing 20 pmol of each primer, 7.5 pmol of dual-labelled 103 
TaqMan® probe and 5 µl total nucleic acid were prepared in an optical reaction plate (Stratagene, 104 
Amsterdam, The Netherlands). For both targets, RT-PCR amplification was performed in an Mx4000 105 
Multiplex Quantitative PCR System (Stratagene) as described previously (34).   106 
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mRT-PCR assay design.  A schematic depiction of the mRT-PCR assay is shown in Figure 1.  The 107 
RT-PCR uses eighteen biotinylated forward and unmodified reverse primer sets (17 for detection, 1 108 
serves as a control).  The sequences that comprise the multiplex assay are shown Table 1. The multiplex 109 
assay was designed to detect and differentiate FMDV from SVDV, VESV, Bovine Viral Diarrhea Virus 110 
(BVDV), Bluetongue Virus (BTV), Parapoxviruses (Orf virus, pseudocowpox virus, and bovine papular 111 
stomatitis virus), and Bovine Herpes Virus-1 (BHV-1).  Primer-probe sequences for FMDV (4, 30) and 112 
BVDV (7, 22) were based on the work of others and adapted to the current multiplex format.  All other 113 
sequences were designed at Lawrence Livermore National Laboratory (LLNL) using an approach that 114 
has previously been described (36).  Additional computational analyses were performed to ensure 115 
specificity and reliability against all available data, including a BLAST-based comparison of each 116 
primer-probe set as a triplet against all sequences in GenBank to identify the targets that are predicted to 117 
produce a PCR or TaqMan reaction at 57 ºC for primer annealing and 67 ºC for probe annealing, where 118 
temperatures are derived from Primer 3 oligo TM calculations.  Optimal candidate primer-probe sets 119 
were forwarded to the bench screening phase for further down-selection.  Amplicon sizes ranged from 120 
95 -349 bp. 121 
mRT-PCR primers and probes.  All oligonucleotides used for mRT-PCR were synthesized by 122 
Integrated DNA Technologies (IDT, Coralville, IA) and HPLC-purified.  Forward primers were 123 
functionalized with 5´ and internal biotin moieties.  Reverse primers were unmodified.  Probes were 5´ 124 
amino C6-modified with an 18-atom hexaethyleneglycol spacer.  Lyophilized probe was dissolved in 2-125 
(N-morphilino)ethanesulfonic acid (MES) to yield a stock concentration of 1 mM.  Lyophilized forward 126 
and reverse primers were dissolved in TE buffer to yield a stock concentration of 1 mM.  Working 127 
dilutions were prepared from the stock solutions as required.   128 
Coupling of probe oligonucleotides to microspheres.  xMAP® Multi-Analyte COOH Microspheres 129 
(Luminex Corp., Austin, TX) were covalently coupled to probe oligonucleotides using carbodiimide 130 
activation based on the manufacturer’s protocol.  Briefly, stock microspheres (1 mL, 1.25x107 131 
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microspheres) were vortexed for 30 s, sonicated for 60 s, centrifuged at 8000 ×g for 5 min and the 132 
supernatant removed.  The microspheres were then resuspended in MES (50 µL, 0.1M, pH 4.5), 133 
vortexed and sonicated.  Probe (10 µL, 50 mM in MES) was added and the mixture vortexed.  An 134 
aqueous solution of N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride (EDC; 5 µL, 10 135 
mg/mL) was added, vortexed, then gently agitated for 30 min in the dark.  A second aliquot of EDC (5 136 
µL, 10 mg/mL) was added, vortexed, then gently agitated for 30 min in the dark.  Tween 20 (1 mL, 137 
0.02% v/v) was added, vortexed, centrifuged, the supernatant removed, then repeated using SDS (1 mL, 138 
0.1% m/v) then TE buffer (100 µL 1 mM Tris, 10 mM EDTA, pH 7.4).  The probe-conjugated 139 
microspheres were resuspended in TE buffer (250 µL), vortexed, then stored at 4°C in the dark.   140 
Microsphere mixture.  A 21-plex microsphere suspension was prepared by combining individual 141 
stock suspensions (9 µL/class) with Tris-NaCl buffer (3 mL).  The mixture was vortexed then 142 
enumerated using the Bio-Plex, targeting approximately 150 microspheres counts per class in 40 s.  If 143 
required, additional microspheres from the individual stocks were added to ensure the concentrations of 144 
all classes were approximately equal. 145 
mRT-PCR amplification.  Each field sample was analyzed in duplicate by the multiplex assay.  146 
Amplification was performed using a one-step RT-PCR kit (SuperScript™ III One-Step RT-PCR 147 
System with Platinum® Taq DNA Polymerase, Invitrogen).  The reaction volume of 25 µL was 148 
comprised of nuclease-free water (0.95 µL), primer mix (3.6 µL), SuperScript™ III 2X reaction mix 149 
(12.5 µL), MgSO4 (0.95 µL, 50 mM, Invitrogen), SuperScript™ III RT / Platinum® Taq Mix (1 µL), 150 
internal control armored RNA (1uL, ~100 copies) and template (5 µL).  The internal control armored 151 
RNA was lysed by heating to 70°C for 4 min prior to addition to the mix.  The final concentration of 152 
each primer and MgSO4 was 0.4 µM and 3.5 mM, respectively. The RT-PCR thermal cycling protocol 153 
was 55°C for 30 min, 95°C for 2 min, then 35 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 15s, 154 
followed by 72°C for 2 min with a final 4°C hold. 155 
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Microsphere array hybridization.  A wash-assay format was adopted to reduce variability of the 156 
response caused by non-specific hybridization of PCR products and fluorescent label.  In a 96-well 157 
plate, RT-PCR product (1 µL) was added to a mixed suspension of probe-conjugated microspheres (22 158 
µL) then placed in a thermal cycler and subjected to 95ºC for 2 min, 55ºC for 5 min, followed by a 4ºC 159 
hold. Tris-NaCl buffer (100 µL, 0.1M Tris, 0.2 M NaCl, 0.05% v/v Triton X-100, pH 8.0, Teknova) was 160 
added and the suspension was transferred to a 96-well vacuum filter plate (MABVN 1250 Multiscreen 161 
Filter Plate, Millipore).  The suspension was vacuum-aspirated, and washed twice with Tris-NaCl buffer 162 
(2 ×100 µL).  Stock streptavidin phycoerythrin (SAPE, 1 mg/mL, Caltag Laboratories) was diluted with 163 
Tris-NaCl to a working concentration of 3 µg/mL.  SAPE (60 µL, 3 µg/mL) was added then incubated 164 
in the dark for 5 min.  The suspension was vacuum-aspirated, washed once with Tris-NaCl (100 µL), re-165 
suspended in Tris-NaCl (100 µL) then transferred to a 96-well round bottom plate for fluorescent 166 
detection.  Nucleic acid extraction, PCR reaction assembly and PCR amplification were conducted in 167 
separate rooms.  Likewise, hybridization and Bio-Plex detection were performed together in a separate 168 
room to minimize the likelihood of PCR contamination by amplicons.  169 
mRT-PCR detection.  Fluorescence detection of the processed microsphere suspension array was 170 
achieved using a Bio-Plex Workstation (Bio-Rad, CA) set to count a minimum of 100 events per 171 
microsphere class in a 50 µL Bio-Plex sample volume.  The Bio-Plex Workstation is a specialized dual-172 
laser flow cytometer integrated with XY microplate platform configured to analyze Luminex xMAP® 173 
microspheres in a 96-well plate format.  The reporter PMT voltage was calibrated on the low setting 174 
with background subtraction enabled.  The Bio-Plex workstation was validated and calibrated per the 175 
manufacturer’s instructions.  The resolution of the MFI was 0.5 units for all channels. 176 
mRT-PCR assay controls.  The multiplex assay incorporates four control channels integral to each 177 
reaction that are used to verify assay integrity.  The negative control (NC) is a microsphere conjugated 178 
to Thermotoga maratima-derived oligonucleotide sequence (MT-7) that serves as a non-specific binding 179 
control in the multiplex PCR assay, and its response should remain consistently low (MFI≤80).  The 180 
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fluorescence control (FC), biotinylated MT-7, confirms that fluorescent labeling with SAPE occurred 181 
and should exhibit a high response (MFI >1000).  The instrument control (IC) comprises a Cy3-labeled 182 
MT-7 conjugate.  As Cy3 and SAPE have similar fluorescence excitation and emission wavelengths, the 183 
IC confirms proper function of the reporter optics within the Bio-Plex flow cytometer (MFI>500).  184 
Armored RNA served as an end-to-end amplification control (AC) to reduce the probability of false 185 
negative and is utilized at low concentrations (100 copies/reaction) to generate a low-level response 186 
(MFI ≥20) which minimizes its competition with detection channels.  The armored RNA (XenoRNA-187 
01, Ambion, Austin, TX) is a proprietary 1070 nucleotide RNA transcript consisting of unique 188 
nucleotide sequences that possess no significant homology to the current annotated sequences in 189 
commonly used sequence databases including NCBI, Affymetrix, and Rosetta.  Primers and probe-190 
labeled microsphere for the AC are included in the multiplex primer mix and microsphere suspension, 191 
respectively.   192 
mRT-PCR assay integrity.  Minimum bead count quota and control channel responses were used to 193 
verify the integrity of the detection channel responses which minimizes the likelihood of false positives 194 
and false-negative results caused by operator error, instrument malfunction, non-specific hybridization, 195 
or PCR inhibition.  The responses of all detection channels are checked against pre-established cut-offs 196 
then identified as mRT-PCR positive, negative or inconclusive.  For each sample, the MFI of each 197 
control bead class was checked against a cut-off value.  A given result was considered invalid when the 198 
MFI value of the IC, NC or FC controls was out of range, or when both the response of the AC was <20 199 
and no detection channels exceeded cut-off. Results were considered valid when the AC was <20 and 200 
any detection channel exceeded cut-off.  The AC response can be diminished by a strong positive 201 
response on a detection channel caused by competition in the RT-PCR reaction.  If the responses of all 202 
control channels are acceptable, the number of beads counted for control and detection channels are 203 
checked (≥40 beads per channel).  If a low bead count for any control channel occurred, then all results 204 
for that sample were considered invalid.  A low bead count on a given detection channel was considered 205 
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an invalid result for the channel in question.   206 
Data analysis.  Raw data exported from the Bio-Plex instrument were imported into MATLAB 207 
(MathWorks) then analyzed using Microsoft Excel.  If at least one result from a duplicate sample 208 
analysis exceed cut-off, the sample was assigned as mRT-PCR positive.  Receiver Operating 209 
Characteristic (ROC) plots (24) were generated using a custom MATLAB program.  Published 210 
guidelines (25) were followed for the calculations of diagnostic test accuracy and statistical methods to 211 
quantify uncertainty.  212 
Cut-off values.  The mRT-PCR responses for this assay are typically non-Gaussian and therefore 213 
non-parametric methods were used to determine cut-offs.  Each channel in the multiplex has a distinct 214 
distribution of responses to true negative samples and therefore each is assigned its own cut-off value. 215 
For each detection channel of the mRT-PCR assay, the responses to true negative samples were ranked 216 
according to magnitude, then cut-off values were identified as the response (MFI value) which gave a 217 
false positive rate closest to 5% (without exceeding 5%), corresponding to a diagnostic specificity of at 218 
least 95% (3D MFI ≥ 6.5, 5´UTR MFI ≥ 5.5).  Other mRT-PCR detection channels for the FMD look-219 
alike disease viruses had similar cut-off values.  For rRT-PCR, the cut-off was Ct ≤32 for both 3D and 220 
5´UTR assays (34).   221 
 222 
RESULTS 223 
 224 
Clinical sample validation.  Receiver Operating Characteristic (ROC) plots were constructed to 225 
compare the diagnostic performance of the 3D and 5´UTR assays in rRT-PCR and mRT-PCR formats 226 
(Figure 2).  For the purpose of this evaluation, VI with Ag-ELISA served as the reference method and 227 
therefore assigned samples as true negative or true positive, with the caveat that rRT-PCR is known to 228 
detect FMDV in some samples considered negative by VI with Antigen-ELISA (35).  Each plot shows 229 
the true positive fraction (TPF; sensitivity) versus the false positive fraction (FPF; 1-specificity) over the 230 
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entire range of cut-off values.  The ROC plots indicate that the 3D and 5´UTR assays in mRT-PCR 231 
format lost some ability to distinguish between true negative and true positive samples, as compared to 232 
rRT-PCR.  The associated areas under each ROC curve also indicate the level of test performance in the 233 
absence of a cut-off value.  Transfer to the multiplex format had the greatest effect upon the 5´UTR 234 
assay where the area under the curve was reduced to 0.773 in comparison to 0.942 for the rRT-PCR 235 
format.  In contrast, the effect upon the 3D assay was less apparent: 0.955 and 0.985 for the mRT-PCR 236 
and rRT-PCR formats respectively.  The ROC plots were generated using 3D and 5´UTR assay results 237 
independently.  In practice, 3D and 5´UTR assay results would be used in combination, an intrinsic 238 
feature of the mRT-PCR format.  The trade-off between TPF and FPF shown by ROC plots can be used 239 
to inform cut-off selection.  The cut-off value for all detection channels was determined from the mRT-240 
PCR response to true negative samples (n=74) using a specificity of 95%.   241 
Table 2 summarizes the performance metrics of the 3D and 5´UTR assays when used independently 242 
or in combination for both formats. Results are presented according to serotype then summarized for all 243 
serotypes.  In some cases, the rRT-PCR response for true positive samples (3D; n=5, 5´UTR; n=9) and 244 
true negative samples (3D; n=5, 5´UTR; n=2) yielded Ct values that were beyond the cut-off.  In 245 
practice, these samples would be considered weak rRT-PCR positives and retested. 246 
Table 3 shows a three-way comparison of mRT-PCR and rRT-PCR against the reference method 247 
using the combined 3D and 5´UTR assay results.  The agreement between mRT-PCR and rRT-PCR for 248 
true positive samples was 95.8% (204/213).  Two samples classified as FMDV-negative by VI and Ag- 249 
ELISA tested positive by both formats (SYR 6/2002, LAO 16/2003).  Similarly, three samples (SYR 250 
7/2002, TUR 17/2002, BHU 5/2004) which were negative by VI and Ag-ELISA tested positive by rRT-251 
PCR but were negative by mRT-PCR due to its higher LOD.  These findings are consistent with earlier 252 
studies (14, 35) where higher analytical sensitivity of rRT-PCR enabled detection of FMDV in samples 253 
designated negative by VI and Ag-ELISA.  Due to its higher LOD, the mRT-PCR missed 9/209 positive 254 
samples detected by rRT-PCR.  Four mRT-PCR false positives had MFI responses that were close to the 255 
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cut-off which was defined using a specificity of 95%.  Four mRT-PCR and rRT-PCR false negatives 256 
were samples of FMDV serotype A (NIG 12/74), C (PHI 2/89) and O (O1 Manisa TUR 8/69, YEM 257 
1/2001).  However, the rRT-PCR did generate Ct responses for two of these samples including PHI 2/89 258 
(3D; 38.94, 5´UTR; 38.51) and O1 Manisa (3D; 32.71).  As the Ct values were beyond the cut-off they 259 
would be considered weak rRT-PCR positives and retested.  These false negatives which generated 260 
either weak or no responses in mRT-PCR and rRT-PCR formats were likely caused by mutations in the 261 
FMDV gene segments targeted by the 3D and 5´UTR assays. They could also be due to low amounts of 262 
virus present, particularly for O1 Manisa, which is a titrated sample used as a positive control in the 263 
diagnostic rRT-PCR that was deliberately set to be only weakly positive. 264 
In addition to the 287 samples used to evaluate the mRT-PCR assay, eleven additional suspect FMDV 265 
field samples of undetermined serotype were analyzed.  These samples were found to be negative by VI 266 
and Ag-ELISA but confirmed positive by combined 3D and 5´UTR rRT-PCR during a previous study.  267 
These samples were analyzed by the mRT-PCR assay, which detected 11/11 of these samples, 268 
demonstrating that the multiplex also detects FMDV in clinical samples that were most likely rendered 269 
non-viable for VI between collection and laboratory receipt. 270 
Limit of detection.  The limit of detection (LOD) of the 3D and 5´UTR assays in mRT-PCR and 271 
rRT-PCR formats were compared using serially diluted clinical samples of serotype O or SAT 2 (Figure 272 
3).  At the defined cut-off values, the mRT-PCR LOD was higher than rRT-PCR by approximately 5-273 
625 times for the 3D assay, and 25-125 times for 5´UTR, depending on serotype.  The higher LOD of 274 
the mRT-PCR therefore caused the loss of diagnostic performance evident in the ROC plots. Further 275 
assay optimization efforts are underway to improve the limits of detection of the 3D and 5´UTR assays 276 
in the mRT-PCR format.    277 
Differential detection.  Characterization of the diagnostic accuracy of the look-alike disease assays 278 
within the mRT-PCR assay is ongoing and will be reported separately.  The mRT-PCR assay was 279 
positive with three SVDV field samples (ITL 4/77, HKN 1/80, HKN 5/91), two VESV isolates 280 
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(serotypes -B51 and -H54), San Miguel sea lion virus (serotypes SMSV-7, -9, -10, -11 and -13) and 281 
cetacean calicivirus (CCV, Tur-1, dolphin).  The mRT-PCR did not detect VESV -B1-34, other VESV 282 
serotypes including bovine (Bos-1 (Tillamook)), feline (A4), reptile (rattlesnake), and skunk, and VSV 283 
(serotype NJ 15/88 CP211634 and Indiana 1 subtype Ind 2 Maipu Argentina).  Feline calicivirus is in a 284 
distinct genomic group from the other VESV viruses tested and was not expected to be detected by this 285 
assay.  mRT-PCR identified look-alike disease viruses in four suspect FMD field samples that had 286 
previously been designated FMDV-negative by VI and rRT-PCR (Figure 4).  Two samples from cattle 287 
(IRN 4/2002, IRQ 58/2002) were mRT-PCR positive for parapoxvirus.  The parapox-3 assay generated 288 
the strongest response, however all three assays exceeded their respective cut-off values for both 289 
samples.  Two further cattle samples (UKG 36/94, UKG 37/94) were mRT-PCR positive for BVDV that 290 
were also confirmed FMDV-negative by all methods.  The mRT-PCR simultaneously detected the co-291 
infection of FMDV and BVDV in a FMDV true positive sample (HUN 2/72).  The presence of BVDV, 292 
which causes a prevalent disease of cattle, did not mask the detection of FMDV.   293 
Cross-talk between detection channels was minimal, even at the relatively high concentrations of 294 
FMDV RNA in many of the field samples tested.  A matrix of correlation coefficients for all channel 295 
pairings was calculated using the results of all FMDV true positive samples (n=213).  The correlation 296 
coefficients of the 3D and 5´UTR channels with other channels did not exceed 0.209 and 0.114, 297 
respectively.   298 
 299 
DISCUSSION 300 
 301 
The mRT-PCR assay was able to detect FMDV at clinically relevant concentrations.  The apparent 302 
concentration of FMDV in the clinical samples was relatively high as might be expected with vesicular 303 
epithelial tissue which, when infected, is rich in virus.  The performance of mRT-PCR and singleplex 304 
rRT-PCRs was compared using VI and Ag-ELISA to define FMDV true positives and true negatives.  305 
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Although VI and Ag-ELISA are established methods for the detection of FMDV, previous studies (14, 306 
35) have demonstrated that rRT-PCR has higher diagnostic sensitivity and can detect virus in additional 307 
samples, which for the purposes of this study would be classified as “true” negatives.  For the majority 308 
of true positive field samples, the 3D mRT-PCR response was saturated and grouped far from the cut-309 
off.  The 5´UTR mRT-PCR signal was generally lower and clustered on either side of the cut-off.  The 310 
higher LOD of both assays in the mRT-PCR format may be caused by low-level non-specific 311 
interactions between primer sets that could reduce amplification efficiency.  The primers used in the 312 
5´UTR assay were not originally designed with multiplexing in mind. In order to recognize a wide range 313 
of FMDV isolates, the 5’UTR primers have a high degree of degeneracy (32-fold and 8-fold for the 314 
forward and reverse primers respectively) that could increase the likelihood of non-specific interactions 315 
with other primer sets in the multiplexed reaction mixture.  Whilst primer probe sets incorporating 316 
degenerate nucleotides can offer broader coverage of highly-variable gene segments, further work is 317 
required to refine their design for multiplexed assays.  Asymmetric PCR and multivariate optimization 318 
may lead to further improvements in the LODs of the 3D and 5´UTR mRT-PCR assays.   319 
The 3D and 5´UTR assay responses had serotypic bias, a finding which agrees with earlier 320 
observations (4, 14).  In mRT-PCR format, the 3D assay was less sensitive for A and C serotypes 321 
whereas the 5´UTR was less effective against SAT serotypes.  For all serotypes collectively, the 3D 322 
assay was more sensitive than the 5´UTR within each format (rRT-PCR 3D 96.7% vs. 5´UTR 87.3%, 323 
mRT-PCR 3D 90.1% vs. 5´UTR 58.7%).  In an earlier evaluation of the rRT-PCR assays (14), the 324 
diagnostic sensitivity of the 3D (97.7 %) was found to be slightly higher than the 5´UTR assay (95.4%).  325 
The diagnostic sensitivity increased when the results of the 3D and 5´UTR assays were used in 326 
combination.  This is due to the “or” nature of the combination, whereby a single mRT-PCR positive 327 
result on the 3D or 5´UTR channel generates a combined mRT-PCR positive result.  The diagnostic 328 
sensitivity of the combined mRT-PCR assay was 93.9%, compared to 98.1% for combined rRT-PCR.  329 
The loss of diagnostic sensitivity from rRT-PCR to mRT-PCR, due to higher limits of detection, was 330 
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partially offset by the inherent ability of the multiplex assay to screen multiple loci simultaneously.  331 
Combined rRT-PCR only increased the diagnostic sensitivity by 1.4% compared to using the 3D rRT-332 
PCR assay in isolation which could factor into the cost-benefit of conducting parallel assays.  As the 333 
mRT-PCR is a screening assay that would most likely be used in conjunction with confirmatory tests, 334 
potential users may be more tolerant of lower specificity in order to achieve higher sensitivity.  The 335 
negative predictive value was also higher for combined assays, because of the “or” nature of the 336 
combined result as false negatives only occurred when both the 3D and 5´UTR results agreed.   337 
The differential detection of FMDV from look-alike disease viruses, which included ssRNA and 338 
dsDNA targets, was demonstrated by testing representative isolates of SVDV, VESV and VSV.  For a 339 
diagnostic laboratory, this could produce time and cost savings, when compared to testing for each 340 
disease using singleplex rRT-PCR assays.  For veterinarians, the mRT-PCR assay could increase 341 
confidence in a sample identified as FMDV-negative by simultaneously screening for the presence of 342 
look-alike diseases.  For networks of veterinary diagnostic laboratories, an mRT-PCR assay could 343 
facilitate embedded foreign animal disease surveillance whilst conducting routine testing of endemic 344 
animal disease viruses.  An inter-laboratory evaluation of this multiplex assay was recently conducted in 345 
fourteen US National Animal Health Laboratory Network laboratories; the results suggested the mRT-346 
PCR technology could be operated successfully in this setting.  The diagnostic performance evaluation 347 
for the look-alike disease assays in the mRT-PCR format is underway and will be reported separately.   348 
The mRT-PCR format is compatible with procedures and instrumentation used for rRT-PCR.  The use 349 
of a single method to prepare clinical samples for mRT-PCR and rRT-PCR analysis was demonstrated 350 
in this study.  The mRT-PCR requires the post-processing of RT-PCR product to the microsphere array 351 
which takes ~50 min per 96-well plate using manually operated multi-channel pipettes. The 96-well 352 
plate format provides convenient interchangeability between manual and automated platforms. With this 353 
reagent set, the Bio-Plex flow cytometer analyzed each well in ~40 s, or ~1 h per 96-well plate.   354 
Although the diagnostic sensitivity of the mRT-PCR for FMDV detection is slightly lower than 355 
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singleplex rRT-PCR, it provides significantly more diagnostic information.  With 17 detection channels 356 
for seven different viruses, the current prototype panel generates 1632 individual assay results per 96-357 
well plate. The microsphere suspension array is a versatile platform compatible with many different 358 
types of diagnostic tests, including immunological and serological assays which could increase its utility 359 
within a veterinary diagnostic laboratory, not only for outbreak response and recovery but also for 360 
routine testing for endemic diseases.  The inherent flexibility of the Luminex array also enables the 361 
composition of a given multiplex assay to be altered by simply adding or removing detection channels.  362 
Refinements to the first version of the mRT-PCR assay described herein are currently underway, 363 
including the development of two species-specific panels for more comprehensive coverage.  These new 364 
panels incorporate additional assays for other FMDV look-alike diseases.  The bovine-specific panel 365 
incorporates assays for FMD, Malignant Catarrhal Fever (MCF), Rinderpest, Bluetongue, BHV-1, 366 
BVD, Parapox and VS.  The porcine-specific panel includes assays for FMD, SVD, VES, VS and 367 
Porcine Reproductive and Respiratory Syndrome (PRRS).   368 
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FIGURE CAPTIONS 498 
 499 
FIG. 1.  Schematic of the multiplex RT-PCR assay.  In the presence of target nucleic acid, the 500 
biotinylated forward primer is extended during the PCR. The PCR product is hybridized to the 501 
microsphere array, whereby the extended forward primer binds to the complementary probe-labeled 502 
microsphere.  The complex is labeled with fluorescent reporter (SAPE) then analyzed using a Bio-Plex 503 
flow cytometer. The fluorescence (570 nm) of bound reporter molecules is measured, and the median 504 
fluorescence intensity is calculated for each microsphere class, then compared to a cut-off to indicate the 505 
presence or absence of a target nucleic acid sequence in a sample. 506 
 507 
FIG. 2.  Receiver Operating Characteristic (ROC) plots for the RNA polymerase (3D) and the 508 
5´untranslated region (5´UTR) assays in singleplex real-time reverse transcriptase PCR (rRT-PCR) and 509 
multiplexed reverse transcriptase polymerase chain reaction (mRT-PCR) formats.  True positive 510 
samples (n=213) representative of all FMDV serotypes and true negative samples (n=74) were 511 
analyzed.  The area under the curves are; 3D rRT-PCR (0.985), 5´UTR rRT-PCR (0.942), 3D mRT-512 
PCR (0.955) and 5´UTR mRT-PCR (0.773). 513 
 514 
FIG. 3.  Comparison of the RNA polymerase (3D) and 5´untranslated region (5´UTR) assay responses 515 
in multiplex RT-PCR and singleplex rRT-PCR formats by consecutive 5-fold serial dilutions of three 516 
different FMDV true positive epithelial suspension samples (undiluted to more dilute from right to left).  517 
The multiplex RT-PCR detection was less sensitive than singleplex rRT-PCR (approximately 5-625 518 
times and 25-125 times, respectively for 3D and 5´UTR signatures).  Cut-off values for rRT-PCR (Ct ≤ 519 
32) and mRT-PCR (3D MFI ≥ 6.5, 5´UTR ≥ 5.5) are indicated by the vertical and horizontal dashed 520 
lines, respectively.  The 5´UTR signature did not respond to the SAT 2 (SAU 4/2000) sample at any 521 
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dilution in singleplex or multiplex formats and was omitted from the plot.  Error bars indicate ±1σ of the 522 
mean (n=2) response from the signature in mRT-PCR format.  For rRT-PCR each sample was analyzed 523 
in singlet (n=1). 524 
 525 
FIG. 4.  Multiplex RT-PCR assay identification of FMDV look-alike disease viruses in suspect FMDV 526 
clinical sample submissions.  The mRT-PCR assay ruled out FMDV whilst simultaneously ruling in 527 
FMD look-alike disease viruses.  A and B show the multi-loci detection of parapox viruses.  C shows 528 
BVDV detection in field samples from cattle (UKG 36/94, UKG 37/94) that were tested FMDV-529 
negative by virus isolation and rRT-PCR and the simultaneous detection of FMDV and BVDV (HUN 530 
2/72).  mRT-PCR cut-offs indicated by the vertical dashed lines were PPOX 1 (≥ 7.5), PPOX 3 (≥ 9.5) 531 
and BVDV (≥ 6.5). The horizontal dashed lines indicate the cut-off for FMDV 3D (≥ 6.5). 532 
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TABLE 1. Primer and probe sequences of the multiplex RT-PCR assay. 533 
Assay name Forward Primer (5´3´) 
Reverse Primer (5´3´) 
Probe (5´3´) 
BHV 1 GŦGCCAGCCGCGŦAAAAG 
GACGACTCCGGGCTCTTTT 
TCCTGGTTCCAGAGCGCTAACATGGAG 
BHV 2 TGAGGCCŦATGTATGGGCAGŦT 
GCGCGCCAAACATAAGTAAA 
AAATAACACGGTGTGCACTTAAATAAGATTCGCG 
BTV 1 GCACCCŦATATGTTŦCCAGACCA 
CAGCTAACTCTTCAGCCACACG 
CTAACTCGTGGGCCAATCATCATCTTCTGT 
BTV 2 AGAATŦCAGGAŦGGGCAGGA 
GCACAATTCCCATCCCCTTA 
CCATCACACCATTATACTGTACCCGCGTAGC 
BVDV GGTAGTCGŦCAGTGGTŦCGAC  
CATGTGCCATGTACAGCAGAGAT 
CCTCGTCCACGTGGCATCTCGAG 
FMDV 3D ACTGGGŦTTTACAAACCŦGTGA 
GCGAGTCCTGCCACGGA 
GTCCCACGGCGTGCAAAGGA 
FMDV 
5´UTR 
CACYTYAAGRŦGACAYTGRTACŦGGTAC 
CAGATYCCRAGTGWCICITGTTA 
CCTCGGGGTACCTGAAGGGCATCC 
PPOX 1 GCAGAŦGCGCTCCŦGGTT 
GCACCTCTGCTGCTGCAA 
CCGACTCCGACGTGGAGAACGTG 
PPOX 2 GATGGCCGŦGCAGCŦCTT 
CGTACAAGATCACGGCCAACT 
TGTACGGGCTCATGGGCTTCCG 
PPOX 3 GCAGCAGŦGCACCACGŦAGT 
CGCTGAACCCGTACATCCT 
GACTTCGAGGCGGACAACAAGCG 
SVDV 1 CAGGAŦAATTTCTŦCCAAGGGC 
ACGTGAACATTTCGAGCTTCC 
TGCATTGTGTCTGATGGTACAACTTGTGACG 
SVDV 2 GACTTGŦTGTGGCŦGGAGGA 
CAGCGCCATGGTGAGGTAG 
TGACCGTAATGAGGTCATCGTGATTTCTCAC 
SVDV 3 GACAAAGŦGGCCAAGGGAAA 
CACGTAAACCACACTGGGCT 
CTGGCGTCATAGCCTGAATAGTCAAACGCTA 
VESV 1 GCCTŦCTCCCTŦCCCAAAA 
TGAAGGAATGGTTCCGTCAGT 
CATCATCGTTGATAACCTTAGATGTGCAATTTGG 
VESV 2 GGGAAŦGAGGTGTGCAŦCATT 
CACGTCTTGATGTTGGCTTGAC 
AAATTGGCATAATCAACCTTGTCAGATGAGTCG 
VESV 3 GGTCGCŦCTCACTGATGAŦGAGTA 
GGTGTTATCAGCACCCATTGC 
GCTCGGTGCCTGAGTTGGAGGAAG 
VESV 4 ACCACCŦCTGGAAACATCŦATGG 
TTTGTGCACGTGTCACGAAT 
CGGGACGGGCATTTGTCACCA 
FC N/A CAAAGŦGGGAGACGTCGŦTG 
IC N/A CAAAGTGGGAGACGTCGTTG-Cy3 
NC N/A CAAAGTGGGAGACGTCGTTG 
 534 
BHV = bovine herpes virus-1, PPOX = parapox virus complex, FMDV = foot-and-mouth disease virus, 535 
BVDV = Bovine Viral Diarrhea Virus, BTV = bluetongue virus, SVDV = swine vesicular disease virus, 536 
VESV = vesicular exanthema of swine virus, NC = negative control, FC = fluorescence control, IC = 537 
instrument control, Cy3 = fluorescent cyanine dye, Y = pyrimidines (C/T), R = purines (A/G), W = 538 
weak 2-bonds (A/T), I = inosine (universal base). Ŧ = an internal biotinylated dT. All forward primers 539 
also include biotinylation at the 5´ terminus.  All probes contain an amine attached to the 5´ terminus 540 
with a carbon 6 and internal spacer 18. N/A = not applicable. 541 
 542 
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TABLE 2.  Performance metrics for the 3D and 5´UTR FMDV assays in rRT PCR and mRT-PCR 543 
formats using independent or combined results. 544 
rRT-PCR mRT-PCR Performance metric 
3D 5´UTR Combined 3D 5´UTR Combined 
Sensitivity (%)      A 
(Fraction)                
93.5 
(43/46) 
87.0 
(40/46) 
97.8 
(45/46) 
80.4 
(37/46) 
76.1 
(35/46) 
93.5 
(43/46) 
Asia 1 100 
(10/10) 
100 
(10/10) 
100 
(10/10) 
100.0 
(10/10) 
100 
(10/10) 
100 
(10/10) 
C 95.0 
(19/20) 
95.0 
(19/20) 
95.0 
(19/20) 
85.0 
(17/20) 
55.0 
(11/20) 
90.0 
(18/20) 
O 96.7 
(87/90) 
86.7 
(78/90) 
97.8 
(88/90) 
91.1 
(82/90) 
70.0 
(63/90) 
92.2 
(83/90) 
SAT 1 100.0 
(18/18) 
88.9 
(16/18) 
100 
(18/18) 
100 
(18/18) 
16.7 
(3/18) 
100 
(18/18) 
SAT 2 100.0 
(21/21) 
71.4 
(15/21) 
100 
(21/21) 
95.2 
(20/21) 
9.5 
(2/21) 
95.2 
(20/21) 
SAT 3 100.0 
(8/8) 
100 
(8/8) 
100 
(8/8) 
100 
(8/8) 
12.5 
(1/8) 
100 
(8/8) 
All 96.7 
(206/213) 
87.3 
(186/213) 
98.1 
(209/213) 
90.1 
(192/213) 
58.7 
(125/213) 
93.9 
(200/213) 
C.I. (95%) 93.4-98.4 82.2-91.1 95.3-99.3 85.4-93.5 52-65.1 89.8-96.4 
Specificity (%) 94.6 95.9 93.2 93.2 94.6 91.9 
C.I. (95%) 86.9-97.9 88.7-98.6 85.1-97.1 85.1-97.1 86.9-97.9 83.4-96.2 
Sample Disease 
Prevalence (%) 74.2 74.2 74.2 74.2 74.2 74.2 
PPV (%) 98.1 98.4 97.7 97.5 96.9 97.1 
NPV(%) 90.9 72.4 94.5 76.7 44.3 84.0 
Efficiency (%) 96.2 89.5 96.9 90.9 67.9 93.4 
Sensitivity is the fraction of the 213 true positive epithelial tissue samples (subjected to both multiplex 545 
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RT-PCR and rRT-PCR assays) that are assigned as FMDV-positive by the indicated assay.  C.I. 546 
Confidence Interval, PPV Positive Predictive Value, NPV Negative Predictive Value. 547 
 548 
TABLE 3.  3-Way comparison table for the combined results of 3D and 5´UTR assays in rRT-PCR and 549 
mRT-PCR formats.  550 
Method Result True Diagnosis 
Combined 
rRT-PCR 
Combined 
mRT-PCR 
Total Samples 
Positive Negative 
Positive Positive 202 200 2 
Positive Negative 12 9 3 
Negative Positive 4 0 4 
Negative Negative 69 4 65 
Total  287 213 74 
 551 
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